ACTiVION-II, the first of two US Phase 3 clinical trials, did not meet co-primary endpoints of VAS pain score and WOMAC® total score at Month ...

As biomanufacturing investment accelerates, workforce readiness has emerged as a critical bottleneck. | Ohio’s $30M training ...

Cohen: Transforming technology use in schools and classrooms is so hard that an intentional break may be the only way to ...

More than 250 million American adults start the new calendar year with a pledge to complete Dry January. By giving up alcohol ...

Highlights combined company’s strong financial position with over $900 million expected at closing, Treeline’s deep clinical-stage pipeline, ...